RNA binding motif protein 22 pseudogene 12Genealiases: []
Q-omics provides the consensus-scored RBM22P12 profile across patient tissues and cancer cell-line models. RBM22P12 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RBM22P12 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, RBM22P12 RNA expression shows 5,149 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight KICH, KIRC, and UCEC as cancer lineages where RBM22P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM22P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM22P12 survival associations across molecular data types. RBM22P12 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM22P12 RNA expression–survival associations across cancer types. High RBM22P12 expression shows unfavorable associations in KICH, MESO, PCPG, LAML, UCEC and LIHC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RBM22P12 RNA expression.
This table summarizes RBM22P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RBM22P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM22P12 shows lower tumor expression in KIRC, KIRP and KICH. The KIRC box plot shows higher RBM22P12 RNA expression in normal versus tumor tissue (log2 FC = −0.160, t-test p < 0.001).
This table shows molecular features associated with RBM22P12 in patient tissues and cancer cell lines. In patient samples, RBM22P12 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
